Abstract
Acquired resistance of cancer cells to various chemotherapeutic agents is known as multidrug resistance, and remains a critical factor in the success of cancer treatment. It is necessary to develop the inhibitors for multidrug resistance. The aim of this study was to examine the effects of eight α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport. Previously established HeLa/SN100 cells, which overexpress ABCG2/BCRP but not ABCB1/MDR1, were used. The effects of the antagonists on sensitivity to mitoxantrone and the transport activity of Hoehst33342, both substrates for ABCG2/BCRP, were evaluated using the WST-1 assay and cellular kinetics, respectively. ABCG2/BCRP mRNA expression and the cell cycle were also examined by real-time RT-PCR and flow cytometry, respectively. Sensitivity to mitoxantrone was reversed by the α-adrenoceptor antagonists in a concentration-dependent manner, although such effects were also found in the parental HeLa cells. Levels of ABCG2/BCRP mRNA expression were not influenced by the antagonists. The transport activity of Hoechst33342 was decreased by doxazosin and prazosin, but unaffected by the other antagonists. In addition, doxazosin and prazosin increased the proportion of S p...Continue Reading
References
Dec 1, 1979·Analytical Biochemistry·G L Peterson
Feb 15, 1985·Science·J L CruiseG K Michalopoulos
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·S M Simon, M Schindler
Apr 12, 1996·The Journal of Biological Chemistry·Z W HuB B Hoffman
Apr 23, 1999·Pharmaceutical Research·R B KimG R Wilkinson
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Jun 26, 2002·Biological & Pharmaceutical Bulletin·Kohji TakaraKatsuhiko Okumura
Sep 13, 2002·Biochimica Et Biophysica Acta·Thomas LitmanSusan E Bates
Sep 17, 2002·International Urology and Nephrology·J L Pool, R S Kirby
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·I E AnglinN Kyprianou
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·N Kyprianou
Jan 25, 2003·The Journal of Urology·Shiow-Lin PanChe-Ming Teng
May 29, 2003·British Journal of Cancer·J V PartinN Kyprianou
Mar 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kiyotaka YohAtsushi Ochiai
May 28, 2004·Expert Opinion on Pharmacotherapy·Anastasios TahmatzopoulosNatasha Kyprianou
Oct 11, 2005·Apoptosis : an International Journal on Programmed Cell Death·A Koceva-ChyłaZ Jóźwiak
May 12, 2006·Molecular Pharmaceutics·Yongling XiaoDavid B Duignan
Sep 18, 2007·The Journal of Urology·Andrew M HarrisNatasha Kyprianou
Oct 6, 2007·International Journal of Cancer. Journal International Du Cancer·Hideki KandaYoshiki Sugimura
Dec 30, 2008·Advanced Drug Delivery Reviews·Kohji NoguchiYoshikazu Sugimoto
Feb 10, 2009·Cancer Letters·Kohji TakaraTeruyoshi Yokoyama
Feb 20, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lin ZhouBo Feng
Jun 23, 2009·The Prostate·Yoshiyuki KojimaKenjiro Kohri
Oct 8, 2009·Oncology Research·Kohji TakaraTeruyoshi Yokoyama
Jan 16, 2010·Nature Reviews. Cancer·Jamie I FletcherMurray D Norris
Jan 6, 2011·Cancer Prevention Research·Yasuhide HoriYoshiki Sugimura
Feb 8, 2011·Toxicology·Dennis Mulac, Hans-Ulrich Humpf
May 5, 2011·The Prostate·Chun-Hou LiaoHong-Jeng Yu
Jul 11, 2013·Urologia Internationalis·Manish GargVishwajeet Singh
Citations
Mar 1, 2014·BMC Research Notes·Toshiho NishitaHideharu Ochiai
Jan 16, 2014·Journal of Experimental & Clinical Cancer Research : CR·Kazuhiro YamamotoMidori Hirai
Mar 20, 2018·Oncology Letters·Tong XieShoufeng Wang
Aug 14, 2012·Archives of Toxicology·Daniel R CioccaStuart K Calderwood